Nat Med
New targeted add-on doubles one-year survival in metastatic pancreatic cancer
Clinical Takeaway: In previously untreated metastatic pancreatic ductal adenocarcinoma, adding the GSK‑3β inhibitor elraglusib to gemcitabine plus nab‑paclitaxel improved median and one‑year survival vs. chemotherapy alone, with manageable toxicity, supporting further phase 3 evaluation.
In metastatic pancreatic ductal adenocarcinoma, median survival is often under a year; few randomized trials in the past decade have shown a meaningful overall survival benefit.
A randomized, international phase 2 trial published in Nature Medicine reports that elraglusib, an oral GSK‑3β inhibitor, significantly improved survival when added to standard first‑line chemotherapy for metastatic pancreatic ductal adenocarcinoma.
The open‑label study enrolled 233 patients across 60 sites in North America and Europe. Participants were randomized 2:1 to receive weekly elraglusib plus gemcitabine/nab‑paclitaxel or chemotherapy alone. At a data cutoff in April 2025, median overall survival was 10.1 months in the elraglusib group vs. 7.2 months with chemotherapy alone, a 2.9‑month improvement corresponding to a 38% reduction in the risk of death (hazard ratio, 0.62).
One‑year survival rates nearly doubled, with 44.1% of patients alive at one year in the elraglusib arm compared with 22.3% in the control arm. Benefits were observed across poor‑prognosis subgroups, including patients with liver metastases.
Toxicities were largely consistent with chemotherapy, though grade 3 or higher neutropenia was more frequent with elraglusib (52.3% vs. 30.8%), as were fatigue and anemia. Investigators also observed increases in intratumoral cytotoxic immune cells, suggesting an immunomodulatory effect in addition to direct antitumor activity.
“While these results will need to be confirmed in phase 3 trials, observing survival benefit in such a difficult‑to‑treat cancer is encouraging,” said lead author Devalingam Mahalingam, MD, PhD. A phase 3 trial is being planned to confirm these findings.
Related epocrates News coverage highlights growing momentum in this space, with the investigational agent daraxonrasib recently reporting a significant overall survival benefit in a pivotal phase 3 trial of metastatic pancreatic cancer.
Source: Mahalingam D, et al. (2026, April 14). Nat Med. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial